Stemline Therapeutics, Inc. announced today the initiation of its second clinical trial for SL-401, a targeted therapy directed to the interleukin-3 receptor present on cancer stem cells and tumor bulk of a wide range of hematologic cancers. This trial will enroll patients with acute myeloid leukemia who have achieved a complete response following their first course of induction chemotherapy, but display evidence of minimal residual disease in their bone marrow and are at high risk for relapse.
http://ift.tt/1zd05UZ
http://ift.tt/1zd05UZ
No comments:
Post a Comment